Form 8-K - Current report:
SEC Accession No. 0001104659-21-061696
Filing Date
2021-05-05
Accepted
2021-05-05 16:01:43
Documents
14
Period of Report
2021-05-05
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K tm2115248d1_8k.htm   iXBRL 8-K 25237
2 EXHIBIT-99.1 tm2115248d1_ex99-1.htm EX-99.1 74620
3 GRAPHIC tm2115248d1_ex99-1img001.jpg GRAPHIC 10929
  Complete submission text file 0001104659-21-061696.txt   297747

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA rigl-20210505.xsd EX-101.SCH 3178
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE rigl-20210505_lab.xml EX-101.LAB 34592
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE rigl-20210505_pre.xml EX-101.PRE 22705
7 EXTRACTED XBRL INSTANCE DOCUMENT tm2115248d1_8k_htm.xml XML 3510
Mailing Address 1180 VETERANS BOULEVARD SOUTH SAN FRANCISCO CA 94080
Business Address 1180 VETERANS BOULEVARD SOUTH SAN FRANCISCO CA 94080
RIGEL PHARMACEUTICALS INC (Filer) CIK: 0001034842 (see all company filings)

EIN.: 943248524 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 000-29889 | Film No.: 21893096
SIC: 2834 Pharmaceutical Preparations